• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Instil Bio, Inc. (NQ: TIL )

    27.63 -1.15 (-4.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Instil Bio, Inc.

    < Previous 1 2 Next >
    Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Instil Bio
    Via GlobeNewswire
    Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Announces Strategic Update
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
    Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells 
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
    From Instil Bio
    Via GlobeNewswire
    NASDAQ:TIL Shareholder Notice: Investigation over Potential Wrongdoing at Instil Bio, Inc.
    San Diego, CA -- (SBWIRE) -- 02/10/2023 -- Certain directors of Instil Bio, Inc. are under investigation over potential breaches of fiduciary duties. 
    Via SBWire
    Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
    From Instil Bio
    Via GlobeNewswire
    Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
    From Instil Bio
    Via GlobeNewswire
    INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating PROG, Fox, Instil, and Twist and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)
    From Newman Ferrara LLP
    Via Business Wire
    Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
    From Instil Bio
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Fox, Instil, Veru, and Twist and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    NASDAQ:TIL Investor Notice: Investigation over Possible Securities Laws Violations by Instil Bio, Inc.
    San Diego, CA -- (SBWIRE) -- 11/16/2022 -- An investigation was announced for investors of Instil Bio, Inc. (NASDAQ:TIL) shares over potential securities laws violations by Instil Bio, Inc.. 
    Via SBWire
    Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
    From Instil Bio
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Establishment, Accelerate Diagnostics, Instil and Unisys and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    From Instil Bio
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Instil and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.